Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission. (1st November 2020)
- Record Type:
- Journal Article
- Title:
- Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission. (1st November 2020)
- Main Title:
- Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission
- Authors:
- Celli, Roberta
Wall, Mark J.
Santolini, Ines
Vergassola, Matteo
Di Menna, Luisa
Mascio, Giada
Cannella, Milena
van Luijtelaar, Gilles
Pittaluga, Anna
Ciruela, Francisco
Bruno, Valeria
Nicoletti, Ferdinando
Ngomba, Richard T. - Abstract:
- Abstract: Previous studies have shown that injection of the mGlu5 receptor positive allosteric modulator (PAM) VU0360172 into either the thalamus or somatosensory cortex markedly reduces the frequency of spike-and-wave discharges (SWDs) in the WAG/Rij model of absence epilepsy. Here we have investigated the effects of VU0360172 on GABA transport in the thalamus and somatosensory cortex, as possible modes of action underlying the suppression of SWDs. Systemic VU0360172 injections increase GABA uptake in thalamic synaptosomes from epileptic WAG/Rij rats. Consistent with this observation, VU0360172 could also enhance thalamic GAT-1 protein expression, depending on the dosing regimen. This increase in GAT-1 expression was also observed in the thalamus from non-epileptic rats (presymptomatic WAG/Rij and Wistar) and appeared to occur selectively in neurons. The tonic GABAA receptor current present in ventrobasal thalamocortical neurons was significantly reduced by VU0360172 consistent with changes in GAT-1 and GABA uptake. The in vivo effects of VU0360172 (reduction in tonic GABA current and increase in GAT-1 expression) could be reproduced in vitro by treating thalamic slices with VU0360172 for at least 1 h and appeared to be dependent on the activation of PLC. Thus, the effects of VU0360172 do not require an intact thalamocortical circuit. In the somatosensory cortex, VU0360172 reduced GABA uptake but did not cause significant changes in GAT-1 protein levels. These findingsAbstract: Previous studies have shown that injection of the mGlu5 receptor positive allosteric modulator (PAM) VU0360172 into either the thalamus or somatosensory cortex markedly reduces the frequency of spike-and-wave discharges (SWDs) in the WAG/Rij model of absence epilepsy. Here we have investigated the effects of VU0360172 on GABA transport in the thalamus and somatosensory cortex, as possible modes of action underlying the suppression of SWDs. Systemic VU0360172 injections increase GABA uptake in thalamic synaptosomes from epileptic WAG/Rij rats. Consistent with this observation, VU0360172 could also enhance thalamic GAT-1 protein expression, depending on the dosing regimen. This increase in GAT-1 expression was also observed in the thalamus from non-epileptic rats (presymptomatic WAG/Rij and Wistar) and appeared to occur selectively in neurons. The tonic GABAA receptor current present in ventrobasal thalamocortical neurons was significantly reduced by VU0360172 consistent with changes in GAT-1 and GABA uptake. The in vivo effects of VU0360172 (reduction in tonic GABA current and increase in GAT-1 expression) could be reproduced in vitro by treating thalamic slices with VU0360172 for at least 1 h and appeared to be dependent on the activation of PLC. Thus, the effects of VU0360172 do not require an intact thalamocortical circuit. In the somatosensory cortex, VU0360172 reduced GABA uptake but did not cause significant changes in GAT-1 protein levels. These findings reveal a novel mechanism of regulation mediated by mGlu5 receptors, which could underlie the powerful anti-absence effect of mGlu5 receptor enhancers in animal models. Highlights: VU0360172 is an mGlu5 receptor positive allosteric modulator. VU0360172 increases GABA uptake and reduces the tonic GABA current in the thalamus. These effects selectively occur in the thalamus and not in the somatosensory cortex. These effects may contribute to the anti-absence effects of VU0360172. … (more)
- Is Part Of:
- Neuropharmacology. Volume 178(2020)
- Journal:
- Neuropharmacology
- Issue:
- Volume 178(2020)
- Issue Display:
- Volume 178, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 178
- Issue:
- 2020
- Issue Sort Value:
- 2020-0178-2020-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-11-01
- Subjects:
- mGlu5 receptors -- Ventrobasal thalamus -- Somatosensory cortex -- GABA uptake -- GAT-1 -- Tonic inhibition
Neuropsychopharmacology -- Periodicals
Autonomic Agents -- Periodicals
Neuropsychopharmacologie -- Périodiques
Neuropsychopharmacology
Periodicals
Electronic journals
615.78 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00283908 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.neuropharm.2020.108240 ↗
- Languages:
- English
- ISSNs:
- 0028-3908
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.517500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14364.xml